atropine has been researched along with olanzapine in 12 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | atropine (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brar, JS; Chengappa, KN; Kirshner, MA; Levine, J; Parepally, H; Pollock, BG; Zoretich, RA | 1 |
| Joosen, MJ; Jousma, E; Kuijpers, WC; Lucassen, PJ; Smit, AB; van den Boom, TM; van Helden, HP | 1 |
| Bourguignon, JJ; Carnicella, S; Mongeot, A; Oberling, P | 1 |
| Andrade, C; Bambole, V; Bang, A; Shah, N; Sonavane, S | 1 |
1 review(s) available for atropine and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for atropine and olanzapine
| Article | Year |
|---|---|
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
Topics: Adult; Antipsychotic Agents; Atropine; Autonomic Nervous System Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Radioligand Assay; Receptors, Muscarinic | 2000 |
10 other study(ies) available for atropine and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Atropine; Benzodiazepines; Cholinesterase Reactivators; Corpus Striatum; Doublecortin Protein; Hippocampus; Male; Maze Learning; Neurogenesis; Olanzapine; Oximes; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Seizures; Soman | 2009 |
Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.
Topics: Animals; Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Conditioning, Classical; Drug Interactions; Haloperidol; Male; Muscarinic Antagonists; Olanzapine; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2010 |
Continuation of ECT after recovery from transient, ECT-induced, postictal cortical blindness.
Topics: Adolescent; Anti-Dyskinesia Agents; Antipsychotic Agents; Atropine; Benzodiazepines; Blindness, Cortical; Electroconvulsive Therapy; Female; Glycopyrrolate; Haloperidol; Humans; Muscarinic Antagonists; Olanzapine; Panic; Schizophrenia, Paranoid; Treatment Outcome; Trihexyphenidyl | 2012 |